CytoDyn Inc.

VANCOUVER, WA · CIK 0001175680 · Biotech · Public

Leronlimab (PRO 140), a monoclonal antibody therapeutic targeting CCR5

cytodyn.com →

Grants: —; No SBIR or STTR on record; Sector median: 1
Raised: $88M; 23 Form D · May 2026; 5 months since last filing
Contracts: —; No federal contracts on record
Patents: 40; 6 granted · 34 pending; Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount

Federal ↑Equity ↓

2008201020122014201620182020202220242026

Capital and federal award history
Date	Event	Source	Amount
20 Oct 2009	Private capital raised	Form D · SEC	$455,000
19 Nov 2009	Private capital raised	Form D · SEC	$250,000
24 Aug 2010	Private capital raised	Form D · SEC	$2,000,000
17 Jan 2012	Private capital raised	Form D · SEC	$2,996,082
05 Sept 2012	Private capital raised	Form D · SEC	$575,500
16 Oct 2012	Private capital raised	Form D · SEC	$5,700,000
25 Sept 2013	Private capital raised	Form D · SEC	$3,207,260
14 May 2015	Private capital raised	Form D · SEC	$3,281,050
14 Jul 2015	Private capital raised	Form D · SEC	$1,972,500
05 Oct 2015	Private capital raised	Form D · SEC	$2,693,800
11 May 2016	Private capital raised	Form D · SEC	$4,301,500
14 Jun 2017	Private capital raised	Form D · SEC	$1,150,000
16 Nov 2017	Private capital raised	Form D · SEC	$1,199,900
10 Sept 2018	Private capital raised	Form D · SEC	$13,199,385
02 Apr 2019	Private capital raised	Form D · SEC	$3,246,000
14 Feb 2020	Private capital raised	Form D · SEC	$7,570,000
30 Mar 2020	Private capital raised	Form D · SEC	$882,000
16 Dec 2020	Private capital raised· 1 of 2 same day	Form D · SEC	$1,000,000
16 Dec 2020	Private capital raised· 2 of 2 same day	Form D · SEC	$1,176,000
16 Sept 2021	Private capital raised	Form D · SEC	$2,872,000
03 Dec 2021	Private capital raised	Form D · SEC	$11,361,000
22 Apr 2022	Private capital raised	Form D · SEC	$1,890,000
11 May 2026	Private capital raised	Form D · SEC	$18,600,392

Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value

Biotech companies ranked by federal contract value
#	Company	Contracts	Disclosed equity
2283	VIACYTE, INC.	—	$150M
2284	EMULATE THERAPEUTICS, INC.	—	$12M
2285	Dicerna Pharmaceuticals, Inc.	—	$90M
2286	CytoDyn Inc.	—	$88M
2287	Geneoscopy, Inc.	—	$58M
2288	MarvelBiome, Inc.	—	$55M
2289	Voyager Therapeutics	—	$119M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 63 related persons

Allen AllenDirector · Executive Officer
Corinne AllenExecutive Officer
CORINNE ALLENExecutive Officer
ALLEN ALLENDirector · Executive Officer
Arvin ArmanExecutive Officer
Tyler BlokExecutive Officer
Karen BrunkeDirector
Karen Brunke, Ph.D.Director
Denis BurgerDirector
Anthony CaraccioloDirector · Executive Officer
Anthony CarracioloDirector
Arian ColachisExecutive Officer
George DembowDirector
GEORGE DEMBOWDirector
Carl DockeryDirector
Ryan DunlapDirector
Craig EastwoodExecutive Officer
Maura FlemingExecutive Officer
Gordon GardinerDirector
Gregory GouldDirector
GREGORY GOULDDirector
George Gould, CPADirector
Gregory Gould, CPADirector
Allan GreenDirector
Robert HoffmanExecutive Officer
Scott KellyDirector · Executive Officer
Scott Kelly, M.D.Director · Executive Officer
Michael KlumpDirector
Jacob LalezariExecutive Officer
Andrew LibbyExecutive Officer
Andrew Libby, Jr.Executive Officer
Antonio MigliareseExecutive Officer
Antonio Migliarese, C.P.A.Executive Officer
Alan MontgomeryDirector
Michael MulhollandExecutive Officer
Jordan NaydenovDirector
JORDAN NAYDENOVDirector
Lishomwa NdhlovuDirector
Lishomwa Ndhlovu, M.D., Ph.D.Director
Michael NobelDirector
S. Michael NobelDirector
Samir Patel, M.D.Director
Richard PestellDirector · Executive Officer
Nadar PourhassanDirector · Executive Officer
Nader PourhassanDirector · Executive Officer
Nader Pourhassan, Ph.DDirector · Executive Officer
Nader Pourhassan, Ph.D.Director · Executive Officer
Mahboob Rahman, M.D., Ph.D.Executive Officer
Nitya RayExecutive Officer
Nitya Ray, Ph.D.Executive Officer
Christopher RecknorExecutive Officer
Christopher Recknor, M.D.Executive Officer
Harish SeethamrajuDirector
Stephen SimesDirector
Alan TimminsDirector
Richard TraugerDirector · Executive Officer
Ronald TroppDirector
RONALD TROPPDirector
Ronald Tropp, Esq.Director
Tanya UrbachDirector
Kenneth Van NessDirector · Executive Officer
KENNETH VAN NESSDirector
David WelchDirector

Patents

USPTO · 6 granted of 40

12 May 2026Methods For Treating Metastatic Colon Cancer With Leronlimabgranted
28 Nov 2024Aav-mediated Expression Of Long-acting ANTI-CCR5 Binding Agents For The Treatment And Prevention Of Hivapplication
21 Feb 2023Inhibition Of CCL5 Ligand Binding To CCR5 Receptor And Alteration Of CCR5/CCL5 Axis Signaling In Inflammation, Cancer, Autoimmune, And Other Conditionsgranted
07 Feb 2023Concentrated Protein Formulations And Uses Thereofgranted
26 May 2022ANTI-CCR5 Agents And Methods Of Treatment That Block Cancer Metastasis Or Enhance Cell Death Induced By Dna Damaging Chemotherapyapplication
15 Jul 2021Method Of Treating Metastatic Triple Negative Breast Cancer (mtnbc) By Administering An Antibody Against C-c Chemokine Receptor Type 5 (CCR5) Antibodyapplication
29 Jun 2021Methods Of Treating Coronavirus Infectiongranted
10 Dec 2020Substitution Monotherapy Treatment For HIV-1 Infection Employing Antibody PRO140application
01 Oct 2020Methods For Reducing Viral Load In HIV-1 Infected Patientsapplication
18 Feb 2020Substitution Monotherapy Treatment For HIV-1 Infection Employing Antibody PRO140granted
10 Dec 2019Methods For Reducing Viral Load In HIV-1 Infected Patientsgranted
21 Mar 2019Screening Methods For Identifying And Treating HIV-1 Infected Patient Sub-populations Suitable For Long Term ANTI-CCR5 Agent Therapyapplication

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.